Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

Tarsus Pharmaceuticals, Inc. ( TARS) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT Good afternoon, and welcome to Tarsus' First Quarter 2026 Financial Results Conference Call. As a reminder, this call ...

Goldman Sachs, Gryphon Investors, MidEuropa and Olympus are among the PE firms eying platform investments and consolidation ...

With sizable and stable EBITDA multiples, ophthalmology assets have become highly sought after by private equity.

In May 2026, Glaukos released an investor presentation outlining its strategy to drive long-term growth by leading a shift toward interventional glaucoma and interventional keratoconus care. The ...

Eye health specialists are cautioning against harmful makeup practices while highlighting nutrient-rich diets and supplements that support vision. Unsafe application techniques and certain ingredients ...

Glaukos Corporation GKOS reported a first-quarter 2026 adjusted loss of 18 cents per share, which came narrower than the ...

The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...

ALLUVIUM showed vamikibart Q8W/Q4W improved DME outcomes but underperformed ranibizumab for BCVA (+4.6 to +7.1 vs +13 letters) and CST reduction (−51 to −68 vs −174 μm). Intraocular inflammation ...